ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00046800
Recruitment Status : Completed
First Posted : October 4, 2002
Last Update Posted : October 20, 2011
Sponsor:
Collaborator:
OSI Pharmaceuticals
Information provided by (Responsible Party):
Astellas Pharma Inc

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Actual Study Completion Date : March 2003